About this trial
The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.
Eligibility criteria
Qualifiers
female emergency medicine patients
≥14 years of age
uncomplicated urinary tract infection
a primary urinary complaint and nitrite-positive urine.
Disqualifiers
pregnancy
abnormal genitourinary tract
recent urinary tract instrumentation
immunosuppression
Trial design
Treatments tested in this trial
- Amikacin
Treatment groups
Sponsors and collaborators
Antonios Likourezos
Lead sponsor
Maimonides Medical Center
Sponsor institution